

Attention:
Ms Michaels
The Society of Hospital Pharmacists of Australia (SHPA)

August 23, 2023

**Re: YERVOY (Ipilimumab)
200mg/40mL Stock
Restrains Resolved**

Dear Ms Michaels,

On behalf of Bristol-Myers Squibb Australia Pty Ltd (BMS), I am writing to inform you that BMS has resumed normal supply of the 200mg vial size of YERVOY® (ipilimumab), following a period of vial-size substitution in late July/early August. Customers no longer need to order and use 50mg vial sizes of YERVOY in substitution for the 200mg vial size.

Patients had continued access to their YERVOY treatment during this temporary period. The 50mg vial size of YERVOY remained available and could be used in substitution of the 200mg vial size.

It would be greatly appreciated if you could disseminate this information to SHPA members.

If you have any questions, please contact the BMS Medical Information Department at 1800 067 567 or via email at: medinfo.australia@bms.com.

Sincerely,

Jamie Lopez, PhD
Associate Medical Director, Oncology & Haematology
BMS Australia and New Zealand